the case for neoadjuvant pembrolizumab in tnbc
Published 2 months ago • 75 plays • Length 1:42Download video MP4
Download video MP3
Similar videos
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
0:56
pembrolizumab as adjuvant therapy for tnbc
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
1:30
keynote-355: hrqol unaffected by the addition of pembrolizumab to chemotherapy for tnbc
-
1:30
emerging immunotherapy beyond checkpoint inhibitors for tnbc
-
0:47
atezolizumab for tnbc
-
1:22
immunological signatures to predict outcomes in patients with tnbc
-
2:07
keynote-355: pembrolizumab in triple-negative breast cancer
-
0:43
management of residual disease in triple negative breast cancer
-
4:24
comment: pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breas...
-
2:50
results for pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer
-
3:26
chemo-immunotherapy for tnbc
-
1:38
combined analyses of pd-l1 and tils for therapy selection in tnbc
-
2:53
neoadjuvant chemoimmunotherapy: keynote-522, i-spy & more
-
5:49
neoadjuvant treatment for triple-negative breast cancer
-
1:35
longer overall survival in metastatic tnbc with pembrolizumab - medpage today